Medicure Inc. (TSXV:MPH)
Canada
· Delayed Price · Currency is CAD | Market Cap | 9.91M |
| Revenue (ttm) | 28.86M |
| Net Income (ttm) | -7.10M |
| Shares Out | 10.44M |
| EPS (ttm) | 0.68 |
| PE Ratio | 1.40 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 2,622 |
| Open | 0.950 |
| Previous Close | 0.950 |
| Day's Range | 0.950 - 0.950 |
| 52-Week Range | 0.830 - 1.430 |
| Beta | 1.00 |
| RSI | 42.49 |
| Earnings Date | Apr 27, 2026 |
About Medicure
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological i... [Read more]
Full Company ProfileFinancial Performance
In 2025, Medicure's revenue was 28.86 million, an increase of 31.72% compared to the previous year's 21.91 million. Losses were -7.10 million, 583.1% more than in 2024.
Financial StatementsNews
Medicure Inc (MCUJF) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Rising Losses
Medicure Inc (MCUJF) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Rising Losses
Q4 2025 Medicure Inc Earnings Call Transcript
Q4 2025 Medicure Inc Earnings Call Transcript
Medicure Earnings Call Transcript: Q4 2025
Net revenue rose to CAD 28.9 million in 2025, driven by pharmacy acquisitions and Marley Drug growth, but net loss widened to CAD 7.1 million due to a CMS rebate, R&D, and amortization. AGGRASTAT revenue declined amid generic competition, while MC-1 phase III trial advanced.
Medicure Reports Financial Results for the Year Ended December 31, 2025 and Schedules April 27, 2026 Conference Call
WINNIPEG, MB / ACCESS Newswire / April 23, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and h...
Medicure Announces Resignation of President and Chief Operating Officer
WINNIPEG, MB / ACCESS Newswire / April 17, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and h...
Medicure Earnings Call Transcript: Q3 2025
Q3 2025 net revenue rose 58% year-over-year to CAD 8.2 million, driven by pharmacy acquisitions and Zypitamag growth, but net loss was CAD 1.4 million due to lower Aggrastat sales and higher costs. MC-1 phase III trial and new chemical entity development remain key priorities.
Medicure Reports Financial Results for Quarter Ended September 30, 2025
WINNIPEG, MB / ACCESS Newswire / November 19, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals an...
Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025
WINNIPEG, MB / ACCESS Newswire / November 13, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceutica...
Medicure Earnings Call Transcript: Q2 2025
Q2 2025 net revenue rose 29% year-over-year to $6.7 million, driven by ZYPITAMAG, MARVEY Drug, and new pharmacy acquisitions, while net loss narrowed and adjusted EBITDA improved. Focus remains on product growth, pharmacy expansion, and R&D for new therapies.
Medicure Reports Financial Results for Quarter Ended June 30, 2025
WINNIPEG, MB / ACCESS Newswire / August 20, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and ...
Medicure to Present Financial Results on August 21, 2025 Call at 8:30 am ET for Quarter Ended June 30, 2025
WINNIPEG, MB / ACCESS Newswire / August 18, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and ...
Medicure Announces Closing of Purchase Agreement for The Acquisition of West Olympia Pharmacy
WINNIPEG, MB / ACCESS Newswire / June 17, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals a...
Medicure Earnings Call Transcript: Q1 2025
Q1 2025 revenue was CAD 5.5 million, with a net loss of CAD 694,000 due to higher R&D and lower AGGRASTAT and ZYPITAMAG insured channel sales. Growth was driven by Marley Drug and new pharmacy acquisitions, while the company remains debt free with stable cash.
Medicure Reports Financial Results for Quarter Ended March 31, 2025 and Annual General Meeting Director Election Results
WINNIPEG, MB / ACCESS Newswire / May 21, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC Pink:MCUJF), a company focused on the development and commercialization of pharmaceuticals an...
Medicure Earnings Call Transcript: Q4 2024
Revenue was stable at CAD 21.9 million, with growth in ZYPITAMAG and Marley Drug offset by lower AGGRASTAT sales. Net loss widened to $1 million due to higher R&D and legal expenses. Pharmacy acquisitions and MC1 clinical progress position the company for future growth.
Medicure to Present Financial Results on April 29, 2025 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2024
WINNIPEG, MB / ACCESS Newswire / April 22, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals ...
Medicure Announces Further Expansion of Its Pharmacy Business Through Signing of a Purchase Agreement for the Acquisition of West Olympia Pharmacy
WINNIPEG, MB / ACCESS Newswire / April 11, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals ...
Medicure Announces Closing of Purchase Agreement for the Acquisition of Gateway Medical Pharmacy
WINNIPEG, MB / ACCESS Newswire / March 11, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals ...
Medicure Announces Expansion of Its Pharmacy Business Through Signing of a Purchase Agreement for the Acquisition of Gateway Medical Pharmacy
WINNIPEG, MB / ACCESS Newswire / February 18, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals an...
Medicure Earnings Call Transcript: Q3 2024
Q3 2024 net revenue was $5.2M, with net income rising to $680K due to a legal settlement. AGGRASTAT revenue declined from generic competition, while Marley Drug and ZYPITAMAG sales grew. R&D focus remains on MC1 for PNPO deficiency and new drug development.
Medicure Reports Financial Results For Quarter Ended September 30, 2024
WINNIPEG, MB / ACCESSWIRE / November 25, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals an...
Medicure to Present Financial Results on November 26, 2024 Call at 8:30 AM ET for Quarter Ended September 30, 2024 and Announces Resignation of Board Member
WINNIPEG, MB / ACCESSWIRE / November 18, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals an...
Medicure Announces Positive Settlement of Product Development and Supply Contracts
WINNIPEG, MB / ACCESSWIRE / October 24, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and...
Medicure Earnings Call Transcript: Q2 2024
Q2 2024 saw net revenue of CAD 5.2 million and a net loss of CAD 1.2 million, driven by higher R&D and cost pressures, with AGGRASTAT revenue declining due to generic competition. Focus remains on MC-1 development and expanding Marley Drug and ZYPITAMAG sales.
Medicure Announces Closing of Asset Purchase Agreement with Canam Bioresearch for Acquisition of Intellectual Property
WINNIPEG, MB / ACCESSWIRE / August 14, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and ...